|Bid||20.67 x 1000|
|Ask||21.08 x 800|
|Day's Range||20.88 - 21.52|
|52 Week Range||18.55 - 41.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH). Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders have […]
Deciphera Pharmaceuticals (DCPH) needs investors to pay close attention to the stock based on moves in the options market lately.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Deciphera Pharmaceut...
The Massachusetts biotech industry's executive shake-up continues, with Deciphera Pharmaceuticals' CEO Mike Taylor stepping down from the company as it approaches its first commercial product.
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Raymond James' Laura Chico initiated coverage of Deciphera Pharmaceuticals with an Outperform rating and $47 price target.